MedTrace Logo

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

NCT04859296 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-20

No results posted yet for this study

Summary

This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.

Conditions

  • Pain
  • Appetite Loss
  • Abuse, Drug

Interventions

DRUG

Placebo

Vaporized placebo

DRUG

Low CBG

Vaporized CBG (5 mg)

DRUG

High CBG

Vaporized CBG (15 mg)

DRUG

Low THC

Vaporized THC (5 mg)

DRUG

High THC

Vaporized THC (15 mg)

Sponsors & Collaborators

Principal Investigators

  • Ziva D Cooper, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2025-12-04
Completion
2026-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859296 on ClinicalTrials.gov